$31.48
3.26% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US80706P1030
Symbol
SRRK
Sector
Industry

Scholar Rock Holding Corp. Stock price

$32.54
-3.69 10.18% 1M
+25.19 342.72% 6M
-10.68 24.71% YTD
+16.82 107.00% 1Y
+18.78 136.48% 3Y
+19.75 154.42% 5Y
+17.04 109.94% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+2.48 8.25%
ISIN
US80706P1030
Symbol
SRRK
Sector
Industry

Key metrics

Market capitalization $3.08b
Enterprise Value $2.71b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-252.05m
Free Cash Flow (TTM) Free Cash Flow $-201.05m
Cash position $437.28m
EPS (TTM) EPS $-2.57
P/E forward negative
P/S forward 116.42
EV/Sales forward 102.35
Short interest 31.23%
Show more

Is Scholar Rock Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Scholar Rock Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Scholar Rock Holding Corp. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Scholar Rock Holding Corp. forecast:

Buy
100%

Financial data from Scholar Rock Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.94 1.94
70% 70%
-
-1.94 -1.94
70% 70%
-
- Selling and Administrative Expenses 66 66
53% 53%
-
- Research and Development Expense 183 183
58% 58%
-
-250 -250
52% 52%
-
- Depreciation and Amortization 1.94 1.94
70% 70%
-
EBIT (Operating Income) EBIT -252 -252
47% 47%
-
Net Profit -246 -246
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Scholar Rock Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Scholar Rock Holding Corp. Stock News

Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targete...
Neutral
Business Wire
18 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be pre...
Neutral
Business Wire
20 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 ...
More Scholar Rock Holding Corp. News

Company Profile

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Jay Backstrom
Employees 196
Founded 2012
Website www.scholarrock.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today